Article Data

  • Views 421
  • Dowloads 117

Original Research

Open Access

Cytoplasmic p21 is responsible for paclitaxel resistance in ovarian cancer A2780 cells

  • X. Xia1,2,3
  • T. Ji3
  • R. Liu3
  • Y. Weng3
  • Y. Fang3
  • Z. Wang2
  • H. Xu4,*,

1Department of Reproductive Center, Peking University Shenzhen Hospital, Shenzhen, China

2Department of Gynecology & Obstetrics, Nanshan People's Hospital, Guangdong Medical College, Shenzhen, China

3Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

4Department of Gynecology & Obstetrics, Shenzhen People's Hospital, Second Clinical Medical College, Jinan University, Shenzhen, China

DOI: 10.12892/ejgo2725.2015 Vol.36,Issue 6,December 2015 pp.662-666

Published: 10 December 2015

*Corresponding Author(s): H. Xu E-mail: crazy332@126.com

Abstract

Purpose: P21 which bound to cyclin-dependent kinase complexes was originally described as a suppressor of cancer cell proliferation, while many recent studies have shown p21, when accumulated in the cell cytoplasm, could promote tumor progression. This study was conducted to investigate the role of p21 in the paclitaxel (PTX) resistance of ovarian cancer. Materials and Methods: Regulation of cytoplasmic p21 was performed through transfection of Akt2 constitutively active vector, Akt2 shRNA and p21 siRNA in the ovarian cancer cell line A2780. Akt2, p-Akt, and p21 expression were examined by Western blot and cell apoptosis rates were assessed by flow cytometry after treatment with PTX. Results: Induction of p21 translocation into the cytoplasm via constitutively active Akt2 transfection in A2780 enhanced the resistance to PTX, while inhibition of p21 translocation into the cytoplasm via Akt2 shRNA transfection in A2780 cells significantly increased PTX treatment sensitivity. Furthermore, knockdown of cytoplasmic p21 by direct p21 siRNA transfection in Akt2 overexpressed A2780 cells notably increased PTX-induced apoptosis. Conclusion: Cytoplasmic p21 may represent a potential therapeutic target for ovarian tumors that are resistant to PTX treatment.

Keywords

Cytoplasmic p21; PTX resistance; Drug resistance; Ovarian cancer; Akt2.

Cite and Share

X. Xia,T. Ji,R. Liu,Y. Weng,Y. Fang,Z. Wang,H. Xu. Cytoplasmic p21 is responsible for paclitaxel resistance in ovarian cancer A2780 cells. European Journal of Gynaecological Oncology. 2015. 36(6);662-666.

References

[1] Flesken-Nikitin A., Hwang C.I., Cheng C.Y., Michurina T.V., Enikolopov G., Nikitin A.Y.: “Ovarian surface epithelium at the junc-tion area contains a cancer-prone stem cell niche”. Nature, 2013, 495, 241.

[2] Verhaak R.G., Tamayo P., Yang J.Y., Hubbard D., Zhang H., Creighton C. J., et al.: “Prognostically relevant gene signatures of high-grade serous ovarian carcinoma”. J. Clin. Invest., 2013, 123, 517.

[3] Abuzeid W.M., Jiang X., Shi G., Wang H., Paulson D., Araki K., et al.: “Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy”. J. Clin. Invest., 2009, 119, 1974.

[4] Kelley S.L., Basu A., Teicher B.A., Hacker M.P., Hamer D.H., Lazo J. S.: “Overexpression of metallothionein confers resistance to anticancer drugs”. Science, 1998, 241, 1813.

[5] Xing H., Weng D., Chen G., Tao W., Zhu T., Yang X., et al.: “Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to doc-etaxel by regulating survivin protein expression in ovarian and breast cancer cells”. Cancer Lett., 2008, 261, 108.

[6] Yang Y.I., Lee K.T., Park H.J., Kim T.J., Choi Y.S., Shih IeM., Choi J.H.: “Tectorigenin sensitizes paclitaxel-resistant human ovarian can-cer cells through downregulation of the Akt and NFκB pathway”. Carcinogenesis, 2012, 33, 2488.

[7] Wu H., Cao Y., Weng D., Xing H., Song X., Zhou J., et al.: “Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms”. Cancer Lett., 2008, 271, 260.

[8] Yang D., Khan S., Sun Y., Hess K., Shmulevich I., Sood A.K., Zhang W.: “Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer”. JAMA, 2011, 306, 1557.

[9] Xu H., Hong F.Z., Li S., Zhang P., Zhu L.: “Short hairpin RNA-me-diated MDR1 gene silencing increases apoptosis of human ovarian cancer cell line A2780/Taxol”. Chin. J Cancer Res., 2012, 24, 138.

[10] Xia X., Ma Q., Li X., Ji T., Chen P., Xu H., et al.: “Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer”. BMC Cancer, 2011, 11, 399.

[11] Rowan K.: “Intraperitoneal therapy for ovarian cancer: why has it not become standard”? J. Natl. Cancer Inst., 2009, 101, 775.

[12] Le X.F., Mao W., He G., Claret F.X., Xia W., Ahmed A.A., et al.: “The role of p27 (Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells”. J Natl. Cancer Inst., 2011, 103, 1403.

[13] Januchowski R., Wojtowicz K., Sujka-Kordowska P., Andrzejewska M., Zabel M.: “MDR Gene Expression Analysis of Six Drug-Resis-tant Ovarian Cancer Cell Lines”. Biomed. Res. Int., 2013, 2013, 241763.

[14] Yang Z.Y., Perkins N.D., Ohno T., Nabel E.G., Nabel G.J.: “The p21 cyclindependent kinase inhibitor suppresses tumorigenicity in vivo”. Nat. Med., 1995, 1, 1052.

[15] Xia W., Chen J.S., Zhou X., Sun P.R., Lee D.F., Liao Y., et al.: “Phos-phorylation/cytoplasmic localization of p21Cip1/WAF1 is associ-ated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients”. Clin. Cancer Res., 2004, 10, 3815.

[16] Besson A., Assoian R.K., Roberts, J.M.: “Regulation of the cy-toskeleton: an oncogenic function for CDK inhibitors”? Nat. Rev. Cancer, 2004, 4, 948.

[17] Koster R., di Pietro A., Timmer-Bosscha H., Gibcus J.H., van den Berg A., Suurmeijer A.J., et al.: “Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer”. J. Clin. Invest., 2010, 120, 3594.

[18] Dong Y, Stephens C, Walpole C, Swedberg JE, Boyle GM, Parsons PG, et al.: “Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian can-cer cells in an ascites mimicking microenvironment”. PLoS One, 2013, 8, e57056.

[19] Zhou B.P., Liao Y., Xia W., Spohn B., Lee M.H., Hung M.C.: “Cy-toplasmic localization of p21Cip1/WAF1 by Akt-induced phospho-rylation in HER-2/neu-overexpressing cells”. Nat. Cell Biol., 2001, 3, 245.

[20] Manning B.D., Cantley L.C.: “AKT/PKB signaling: navigating downstream”. Cell, 2007, 129, 1261.

[21] Yuan Z.Q., Sun M., Feldman R.I., Wang G., Ma X., Jiang C., et al.: “Frequent activation of AKT2 and induction of apoptosis by inhibi-tion of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer”. Oncogene, 2000, 19, 2324.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top